Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Soquelitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Corvus Pharmaceuticals Announces Data from Soquelitinib Trial
    Corvus Pharmaceuticals Announces Data from Soquelitinib Trial

    18 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/18/2998957/0/en/Corvus-Pharmaceuticals-Announces-Interim-Data-from-Placebo-Controlled-Phase-1-Clinical-Trial-of-Soquelitinib-for-Atopic-Dermatitis.html

    GLOBENEWSWIRE
    18 Dec 2024
    Share Share
    Corvus Pharma Initiates Phase 3 Trial Of Soquelitinib For PTCL
    Corvus Pharma Initiates Phase 3 Trial Of Soquelitinib For PTCL

    10 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/10/2943658/0/en/Corvus-Pharmaceuticals-Initiates-Registrational-Phase-3-Clinical-Trial-of-Soquelitinib-for-Patients-with-Relapsed-Refractory-Peripheral-T-Cell-Lymphoma.html

    GLOBENEWSWIRE
    10 Sep 2024
    Share Share
    Corvus Pharma Reports Q2 2024 Results And Business Update
    Corvus Pharma Reports Q2 2024 Results And Business Update

    06 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/06/2925408/0/en/Corvus-Pharmaceuticals-Provides-Business-Update-and-Reports-Second-Quarter-2024-Financial-Results.html

    GLOBENEWSWIRE
    06 Aug 2024
    Share Share
    Soquelitinib Shows Promise For Inflammatory Diseases In Preclinical Data
    Soquelitinib Shows Promise For Inflammatory Diseases In Preclinical Data

    25 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/25/2918828/0/en/Publication-of-Preclinical-Data-in-Science-Signaling-Demonstrated-the-Potential-of-ITK-Inhibition-with-Soquelitinib-as-a-Novel-Approach-to-Treatment-of-Inflammatory-Diseases.html

    GLOBENEWSWIRE
    25 Jul 2024
    Share Share
    Corvus Provides Business Update, Q1 2024 Financial Results
    Corvus Provides Business Update, Q1 2024 Financial Results

    06 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/06/2876123/0/en/Corvus-Pharmaceuticals-Provides-Business-Update-and-Reports-First-Quarter-2024-Financial-Results.html

    GLOBENEWSWIRE
    06 May 2024
    Share Share
    Corvus: Soquelitinib Phase 1 Clinical Trial for Atopic Dermatitis
    Corvus: Soquelitinib Phase 1 Clinical Trial for Atopic Dermatitis

    09 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/09/2860339/0/en/Corvus-Pharmaceuticals-Announces-Initiation-of-Placebo-Controlled-Phase-1-Clinical-Trial-of-Soquelitinib-for-Atopic-Dermatitis.html

    GLOBENEWSWIRE
    09 Apr 2024
    Share Share